Red Blood Cell & Iron Disorders

Red Blood Cell & Iron Disorders

A collection of features and news articles published in ASH Clinical News related to red blood cell and iron disorders.

Luspatercept-aamt Approved for Anemia in Adults With MDS

The FDA has approved luspatercept-aamt for the treatment of anemia that requires 2 or more red blood cell transfusions over 8 weeks in adults...
You Make the Call

You Make the Call: Would rituximab re-treatment help this patient with hemolytic anemia?

This month, Edward Benz Jr., MD, discusses treatment of Coombs-positive hemolytic anemia in a patient who declines to undergo splenectomy.I am caring for a...

Comparing Risks of Hypophosphatemia With Intravenous Formulations in Iron-Deficiency Anemia

For patients with iron-deficiency anemia who are intolerant of or unresponsive to oral iron, intravenous formulations can rapidly correct iron deficiency, but certain formulations...

Luspatercept Reduces Anemia Severity, Improves Rate of Transfusion Independence in MDS

Compared with placebo, treatment with luspatercept improved the 12- to 16-week rate of red blood cell (RBC) transfusion independence in patients with lower-risk myelodysplastic...

Sickle Cell Disease Gene Therapy Receives Orphan Drug Designation

ARU-1801, an investigational gene therapy for the treatment of sickle cell disease (SCD) and beta thalassemia, was granted orphan drug designation by the FDA. ARU-1801...
Sickle cell anemia

ICER Report Finds That Sickle Cell Drugs Are Too Expensive

According to a draft report by the Institute for Clinical and Economic Review (ICER), SCD drugs made by Novartis, Global Blood Therapeutics (GBT), and...

FDA Approves Ferric Derisomaltose for Iron-Deficiency Anemia

The ferric derisomaltose injection received FDA approval for the treatment of iron-deficiency anemia in adults who are intolerant to oral iron, whose disease has...

FDA Approves Voxelotor for Sickle Cell Disease

The FDA has approved voxelotor, a once-daily oral therapy that modulates hemoglobin affinity for oxygen by binding to hemoglobin S and stabilizing it, to...
Sickle cell anemia

Crizanlizumab-tmca Becomes First Approved Targeted Therapy for Sickle Cell Disease

The FDA approved crizanlizumab-tmca to reduce the frequency of vaso-occlusive crisis in patients aged 16 and older with sickle cell disease (SCD). The agent...

Luspatercept-aamt Approved to Treat Anemia in Beta Thalassemia

The FDA approved luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. The approval...
Advertisement

Current Issue

May 2020, Volume 6, Issue 6

This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.